F11R and Miyoshi myopathy: Interestingly, correlative studies from the Phase I trial demonstrated that patients’ MM cells did not display significant JAM-1 expression, consistent with RV resistance and the necessity of sufficient viral entry to mediate tumour cell killing90, 95.